it could take weeks to get that in place. there is clear evidence the boosters can benefit some portion of the population. debate within the fda and cdc today will be what population can benefit the most from boosters. if you look at the data coming out of israel collecting good data seems to show people above the age of 60 vaccinated a long interval ago benefit from boosters with reduction in infection and cases of severe infection. there is a population for whom these shots could benefit. dana: what about side effects from a third shot, a booster shot? do we know anything about that? look, the safety profile with the third shot looks consistent with the profile of the second shot. same kind of sight effects. injection site reaction, fever. looks to be less if you look at the israeli datasets. that s in an older population. what the u.s. regulators want to do is make the boosters initially available for an